Pharmaceuticals News and Research

RSS

New findings could deliver low-cost method to extract anticancer compound

A popular cancer drug could be produced cheaply and sustainably using stem cells derived from trees, a study suggests. Researchers have isolated and grown stem cells from a yew tree whose bark is a natural source of the anticancer compound paclitaxel. The development could enable the compound to be produced on a commercial scale at low cost, with no harmful by-products.

26 Oct 2010

India's Trade Minister says EU will take steps to prevent seizure of generic medicines

"India believes a row with the European Union over seizures of generic drugs will be settled without litigation, Trade Minister Anand Sharma said on Wednesday," Reuters reports (Lynn, 10/20).

26 Oct 2010

Lumiphore signs global cooperation with Algeta to integrate Lumi4 complexes

Lumiphore Inc., a portfolio company of Nanostart AG, has signed a global cooperation with Algeta ASA a leading company specializing in innovative radiopharmaceutical therapies to treat cancer patients. The agreement enables the integration of Lumiphore's Lumi4 complexes into the targeted radiotherapeutics and companion diagnostics from Algeta.

From Thermo Fisher Scientific Inc. 26 Oct 2010

PharmaVentures acts as advisor and broker to Dr Reddy's in distribution agreement with Vitabiotics

PharmaVentures Ltd announced today that it had acted as the advisor and broker to the Indian pharmaceutical company Dr Reddy's Laboratories in its successful marketing and distribution agreement with the UK healthcare company Vitabiotics Ltd for a range of nutraceutical products. The agreement provides Dr Reddy's exclusive marketing rights in the Russian/CIS markets for two of Vitabiotics' leading products - Jointace and Dietrim. Vitabiotics will supply these products on a long-term basis from its facilities in Europe.

From Vitabiotics Ltd. 26 Oct 2010

PAREXEL's white paper provides data on biopharmaceutical, medical device product development

PAREXEL Consulting, a business unit of PAREXEL International and a leading global life sciences consultancy serving the biopharmaceutical and medical device industries, today released a new white paper entitled Drug Innovation, Approval, Market Access, and the New Normal Emerging FDA Review Outcome Trends for New Drugs.

From Parexel 26 Oct 2010

OpenTrust to secure wireless network access for 4,000 iPhone, iPad users of global pharma company

OpenTrust, the Next-Gen IT security software publisher, today announced that it will secure wireless network access for users of 4,000 iPhones and iPads for a leading global organization.

26 Oct 2010

Independent drugstores expand and generate strong profits despite worst economy

Amidst the worst economy of the past seventy years, independent drugstores are expanding and generating strong profits, according to a new economic report by the National Community Pharmacists Association (NCPA). The report shows that there are almost 400 more independent drugstores than last year and that profits (3.2%) are three times greater than the rate of U.S. inflation (1.1%).

26 Oct 2010

Techulon signs exclusive license with Virginia Tech to market new theranostic transfection reagent

Techulon™ Inc., an early stage life sciences company based in the Virginia Tech Corporate Research Center, has signed an exclusive license with Virginia Tech Intellectual Properties Inc. to market a new theranostic transfection reagent. This new traceable reagent complements Techulon's currently marketed Glyocofect™ transfection platform and expands the company's offering in an $800 million market that is steadily growing at 15% annually.

26 Oct 2010

Pharmacopeias of US and Kazakhstan sign accord

With the mutual goal of improving the quality of pharmaceuticals worldwide, the United States Pharmacopeial Convention (USP) and the Republican State Enterprise (RSE) National Centre for Expertise of Drugs, Medical Products and Equipment ("the Centre") of the Ministry of Health of the Republic of Kazakhstan have entered into an agreement to share standards for the quality, purity, strength and identity of medicines.

26 Oct 2010

Pfizer's Sutent stands as first-line setting for treating renal cell carcinoma: Survey

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of renal cell carcinoma (RCC), the majority of surveyed European oncologists who favor Pfizer's Sutent indicate that they would switch to an emerging therapy only if it extended progression-free survival (PFS) by at least an additional two to three months, assuming the agent's safety and tolerability profile was comparable to that of Sutent.

26 Oct 2010

IDC grants MedImmune global rights to GLA adjuvant

Immune Design Corp. (IDC), a privately held biotechnology company developing novel vaccines and immunotherapies for infectious disease and cancer, announced today that it has entered into a license and development agreement with MedImmune for the use and commercialization of IDC’s proprietary Glucopyranosyl Lipid Adjuvant (GLA) as a component in vaccines for select infectious diseases.

26 Oct 2010

DKSH’s distribution centers achieve GMP/GDP certification

On the occasion of DKSH's Annual Logistics and Quality Seminar in Taipei, Business Unit Healthcare organized a Certification Award Ceremony to acknowledge the great success of the certification program. It was presided by Charles Toomey, Executive Vice President Business Unit Healthcare, and Dr. Eize de Boer from SGS (Société Générale de Surveillance).

26 Oct 2010

Momenta receives patent for methods to evaluate enoxaparin

Momenta Pharmaceuticals, Inc. a biotechnology company specializing in the characterization and engineering of complex drugs, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,816,144, entitled "Evaluating Mixtures of Low Molecular Weight Heparins By Chain Profiles or Chain Mapping". The patent includes claims to methods of analyzing and processing enoxaparin by analyzing chain sequence information.

26 Oct 2010

Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome

Celtic Therapeutics Holdings L.P. a successor firm to Celtic Pharma, and Resolvyx Pharmaceuticals, Inc. (Resolvyx) announced today that they have entered into an option agreement relating to Resolvyx's RX-10045, a late-stage program for the treatment of dry eye syndrome and other ophthalmic conditions.

26 Oct 2010

Savient to evaluate strategic alternatives for KRYSTEXXA drug

Savient Pharmaceuticals, Inc. announced that its previously announced process to identify, following the approval of KRYSTEXXA by the U.S. Food and Drug Administration (FDA), a strategic transaction for the sale of the Company did not result in a sale of the Company at this time. The board of directors will continue to evaluate strategic alternatives available to the Company to maximize value.

26 Oct 2010

Trius receives patent protection for torezolid phosphate in the U.S.

Trius Therapeutics, Inc. announced today the issuance of Patent Number 7,816,379, entitled "Oxazolidinone Derivatives," by the United States Patent and Trademark Office (USPTO). The new patent, which is exclusively licensed to Trius, protects the Company's lead investigational drug, torezolid phosphate (TR-701), currently in Phase 3 clinical testing in patients with acute bacterial skin and skin structure infections (ABSSSI).

26 Oct 2010

TRACON to present data on TRC105, TRC102 cancer therapies at EORTC-NCI-AACR Symposium

TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and related diseases, announced today that new data on TRC105 and TRC102 will be presented at the 22nd Annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany.

26 Oct 2010

PhRMA representatives meet with officials in India to discuss compulsory licensing

During a visit with government officials, industry leaders and NGOs in India last week, representatives from Pharmaceutical Research and Manufacturers of America (PhRMA), a U.S. lobbying group that represents the country's pharmaceutical industry and biotechnology companies, addressed "the Indian government's proposal to allow local drugmakers to make low-cost version of patented drugs so that they can be made available to patients," the Economic Times reports.

26 Oct 2010

Maven Semantic updates Lymphocyte Cell Biology research database

Maven Semantic announces updates to their Lymphocyte Cell Biology research database. The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector.

26 Oct 2010

ARIAD's oral ridaforolimus improves PFS in patients with metastatic endometrial cancer

Pharmaceuticals, Inc. today announced interim results of a randomized, open‐label, active-control multicenter Phase 2 study of oral ridaforolimus, an investigational mTOR inhibitor, in patients with metastatic or recurrent endometrial cancer. Based on this interim analysis, the study demonstrated a statistically significant improvement in the primary endpoint of median progression-free survival (PFS) in patients receiving single-agent ridaforolimus compared to patients receiving standard-of-care treatment.

26 Oct 2010

Pharmaceuticals News and Research

New findings could deliver low-cost method to extract anticancer compound

India's Trade Minister says EU will take steps to prevent seizure of generic medicines

Lumiphore signs global cooperation with Algeta to integrate Lumi4 complexes

PharmaVentures acts as advisor and broker to Dr Reddy's in distribution agreement with Vitabiotics

PAREXEL's white paper provides data on biopharmaceutical, medical device product development

OpenTrust to secure wireless network access for 4,000 iPhone, iPad users of global pharma company

Independent drugstores expand and generate strong profits despite worst economy

Techulon signs exclusive license with Virginia Tech to market new theranostic transfection reagent

Pharmacopeias of US and Kazakhstan sign accord

Pfizer's Sutent stands as first-line setting for treating renal cell carcinoma: Survey

IDC grants MedImmune global rights to GLA adjuvant

DKSH’s distribution centers achieve GMP/GDP certification

Momenta receives patent for methods to evaluate enoxaparin

Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome

Savient to evaluate strategic alternatives for KRYSTEXXA drug

Trius receives patent protection for torezolid phosphate in the U.S.

TRACON to present data on TRC105, TRC102 cancer therapies at EORTC-NCI-AACR Symposium

PhRMA representatives meet with officials in India to discuss compulsory licensing

Maven Semantic updates Lymphocyte Cell Biology research database

ARIAD's oral ridaforolimus improves PFS in patients with metastatic endometrial cancer

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence